

# MVIS US Listed Pharmaceutical 25 Index

The modified market cap-weighted index tracks the performance of the largest and most liquid US-listed companies that derive at least 50% of their revenues from pharmaceuticals. The pure-play index contains only companies which are engaged primarily engaged in research (incl. research contractors) and development as well as production, marketing and sales of pharmaceuticals. Pharmacies are excluded. The MVIS US Listed Pharmaceutical 25 Index (MVPPH) has been licensed to underlie financial products with currently USD 230.19 million in assets under management.

## Key Features



	All Time High/Low	52-Week High/Low
<b>Total Return Net Index</b>	3494.07/560.95	3494.07/2729.84

### Size and Liquidity Requirements

Full MCap of at least 150 mln USD. Three month average-daily-trading volume of at least 1 mln USD at a review and also at the previous two reviews. At least 250,000 shares traded per month over the last six months at a review and also at the previous two reviews.

### Pure-Play

Companies have to generate at least 50% revenues from pharmaceuticals.

### Diversification

Company weightings are capped at 20%.

### Review

Semi-annually.

## Index Data

### INDEX PARAMETERS

<b>Launch Date</b>	12 Aug 2011	<b>Components</b>	25
<b>Type</b>	Sector	<b>Volatility (1 year)</b>	14.66
<b>Currency</b>	USD	<b>Full MCap bn USD</b>	2,479.24
<b>Base Date</b>	29 Sep 2000	<b>Float MCap bn USD</b>	2,034.06
<b>Base Value</b>	1,000.00	<b>Correlation* (1 year)</b>	0.8472

\* MSCI ACWI Pharmaceuticals

### FUNDAMENTALS\*

<b>Price/Earnings Trailing</b>	-108.27
<b>Price/Book</b>	3.00
<b>Price/Sales</b>	0.95
<b>Price/Cash Flow</b>	11.09
<b>Dividend Yield</b>	2.03

\* as of 31 May 2021


### ANNUALISED PERFORMANCE\*

<b>1 Month</b>	1.45%
<b>1 Year</b>	20.47%
<b>3 Years</b>	9.15%
<b>5 Years</b>	6.56%
<b>Since Inception</b>	6.09%


\* Total Return Net Index

## Country and Size Weightings

Country	Count	Weight
United States	14	59.03%
United Kingdom	3	10.38%
Denmark	1	5.02%
France	1	5.00%
Switzerland	1	4.98%
Ireland	2	4.52%
Japan	1	4.44%
Israel	1	3.60%
Canada	1	3.03%



- US
- GB
- DK
- FR
- CH
- IE
- JP
- IL
- CA




- Large-Cap
- Mid-Cap
- Small-Cap
- Micro-Cap

Size	Count	Weight
Large-Cap (> 6 bn)	23	98.82%
Mid-Cap (1.5 bn - 6 bn)	2	1.18%
Small-Cap (0.2 bn - 1.5 bn)	0	0.00%
Micro-Cap (0.0 bn - 0.2 bn)	0	0.00%

## MVIS US Listed Pharmaceutical 25 Index

### Sector Weightings

Sector	Count	Weight
Health Care	25	100.00%



### Index Components

Top Components by Weight	Country	Weight	Best Performing Components	YTD	1 Day
ASTRAZENECA PLC-SPONS ADR	GB	5.23%	VIATRIS INC	-21.96%	0.97%
MERCK & CO. INC.	US	5.22%	NOVO-NORDISK A/S-SPONS ADR	21.15%	0.65%
ELI LILLY & CO	US	5.08%	ELI LILLY & CO	37.02%	0.50%
BRISTOL-MYERS SQUIBB CO	US	5.07%	ZOETIS INC	13.93%	0.49%
NOVO-NORDISK A/S-SPONS ADR	DK	5.02%	MERCK & CO. INC.	0.71%	0.46%
SANOFI-ADR	FR	5.00%			
NOVARTIS AG-ADR	CH	4.98%			
JOHNSON & JOHNSON	US	4.95%	<b>Worst Performing Components</b>	<b>YTD</b>	<b>1 Day</b>
ABBVIE INC	US	4.93%	AMARIN CORPORATION PLC -ADR	-8.38%	-3.45%
PFIZER INC	US	4.91%	Teva Pharmaceutical Industries ADR	3.94%	-2.15%
ZOETIS INC	US	4.79%	JAZZ PHARMACEUTICALS PLC	8.47%	-1.59%
GLAXOSMITHKLINE PLC-SPON ADR	GB	4.55%	ORGANON & CO	-8.12%	-1.26%
<b>Subtotal</b>		59.71%	SANOFI-ADR	11.39%	-0.96%

### Symbols

	Symbol	ISIN	WKN	Sedol	Bloomberg	Reuters	Telekurs
<b>Price Index</b>	MVPPH	DE000SLA0LS2	SLA0LS	B4RGLR2	MVPPH	.MVPPH	13624427
<b>Total Return Net</b>	MVPPHTR	DE000SLA0LT0	SLA0LT	B4LWXJ2	MVPPHTR	.MVPPHTR	13624431
<b>Total Return Gross</b>	MVPPHTRG	DE000SLA1CM2	SLA1CM	B88HTJ0	MVPPHTRG	.MVPPHTRG	20729426

For further information visit [www.mvis-indices.com](http://www.mvis-indices.com)

Nothing on this factsheet shall be considered a solicitation to buy or an offer to sell a security, or any other product or service, to any person in any jurisdiction where such offer, solicitation, purchase or sale would be unlawful under the laws of such jurisdiction. Neither MV Index Solutions GmbH nor any of its licensors makes any warranties or representations, express or implied, to the user with respect to any of the data contained herein. The data is provided for informational purposes only, and the Company shall not be responsible or liable for the accuracy, usefulness or availability of any information transmitted or made available through it. The MVIS® indices are protected through various intellectual property rights and unfair competition and misappropriation laws. In particular, Van Eck Associates Corporation has registered the "MVIS" trademark. You require a licence to launch any product whose performance is linked to the value of a particular MVIS® index and for all use of the MVIS® name or name of the MVIS® index in the marketing of the product. All information shown prior to the index launch date is simulated performance data created from backtesting ("simulated past performance"). Simulated past performance is not actual but hypothetical performance based on the same or fundamentally the same methodology that was in effect when the index was launched. Simulated past performance may materially differ from the actual performance. Actual or simulated past performance is no guarantee for future results.